			Name (Last, First, MI.)			Exam Date (mm-dd-yyyy)				
			Birth Date (mm-dd-yyyy)	Passport Number				ien (<i>Case</i>) Number		
1. Pas	t Medi	cal Histo	ory							
No					No	Yes				
		General Illness or injury requiring hospitalization (including psychiatric)					Pregnancy	s and Sexually Transmitted Diseases v, current ed delivery date (mm-dd-yyyy)		
		Arrhyth Rheum	ension stive heart failure or coronary arter	y disease			Pregnancy, birth dates (mm-dd-yyyy) Previous treatment for sexually transmitted diseases, specify date (mm-yyyy) and treatment:			
		Pulmonology Tobacco use: Current Former Asthma Chronic obstructive pulmonary disease Tuberculosis history: Diagnosed (mm-yyyy) Treated (mm-yyyy)					Chancroid Gonorrhea Granuloma inguinale Lymphogranuloma venereum Syphilis			
		Fever Cough Night s Weight	sweats				Endocrino Diabetes m Thyroid dis	nellitus		
		 Weight loss Psychiatry Major impairment in learning, intelligence, self-care, memory, or communication Major mental disorder (including bipolar disorder, major depression, mental retardation, post-traumatic stress disorder, schizoaffective disorder, schizophrenia) Use of drugs other than those required for medical reasons Addiction (dependence) or abuse of specific substances or drugs on the CSA Other substance related disorders (including alcohol abuse or dependence) Ever caused serious injury to others, caused major property damage or had trouble with the law because of medical condition, mental disorder, or influence of alcohol or drugs Ever had thoughts of harming yourself Ever acted on those thoughts Ever acted on those thoughts Neurology 					Anemia Sickle Cell Thalassem Other hemo Other HIV: if prev Wears glas Malignancy Chronic rer Chronic live Hansen's E Treate Other medi			
		Seizure	v of stroke e disorder							
		inform	ant appears to be providing unre ation, specify in remarks	eliable or false						
	Photo	ledicatio	Dins (List all current medications)	U.S. De MEDICAL CAL EXAMI For Us	partmer HIS	nt of Sta FOR TON	Te Y AND WORK	ESTIMATED BURDEN: 30 MINU		
				DRA	AFT6			Page 1 of 3		

A Vitel Signe and Vision													
4. Vital Signs and Vision													
Hei	leight cm BP /								Date (mm-dd-yyyy) perature oC	End Da Visual acuity at	End Date <i>(mm-dd-yyyy)</i> Visual acuity at 20 feet:		
	Bulan (min								Uncorrected L	20/ R 20/			
Wei	ght —		—— kg	Pulse		/ min		1.	piratory				
BMI kg/m2								Rate / min Corrected L 20/ R 20/					
5. P	5. Physical Examination (include all findings and give details in Remarks)												
N, normal; A, abnormal													
		Genera	l appearance						Inguinal region (includin	g adenopathy)			
			nal status <i>(inc</i>	luding a	acute wa	asting and or			Musculoskeletal system	,			
			nic stunting m			5] 🗆	Extremities (including po				
			and ears							,	nesia consistent with Hansen's		
		Eyes	,					_	Disease, evidence of				
		-	nouth, and thr	oat (incl	luda dat	ail)		_	Hematologic (including		- ,		
			51, S2, murmi	•		unj			Lymph nodes	0			
		•	51, 32, mumu	ur, 100)] 🗆	Nervous system (includi	ing nerve enlargeme	ent)		
		ungs			()				, ,	• •	e, perception, thought processes		
			en (including l a (including ir							behavior during examination)			
6. N	1 1		Specialist	liection(5))								
			le to mental h	ealth sp	ecialist.	lf so. attach	report.						
			atory Results										
_			esting not don		cutifici								
	Labor	alory le	esting not uon	C									
	Test Name Date specim												
			Test	Name		•	cimen o -dd-yy		ed Positive	Negative	Initial Titer		
Sc	reening	g	Test	Name		•			ed Positive	Negative	Initial Titer		
	reening		Test	Name		•			ed Positive	Negative	Initial Titer		
Co		tory	Test ated, therapy:			•			ed Positive Date(s) treatment g		Initial Titer		
Co Tr	onfirma	tory If tre		 	2.4 MU	(mn					Initial Titer		
Co Tr	onfirma eated	tory If tre	ated, therapy:	: enicillin,		(mn					Initial Titer		
Co Tr	onfirma eated Yes	tory If tre	ated, therapy: Benzathine pe Other (therap	: enicillin, y, dose)	:	(mm	o-dd-yy	<i>yy)</i>			Initial Titer		
Co Tr	onfirma eated Yes	tory If tre	ated, therapy: Benzathine pe Other (therapj ted by panel I	enicillin, <i>y, dose)</i> ohysicia	n:	(mn	o-dd-yy				Initial Titer		
Co Tr	onfirma eated Yes	tory If tre	ated, therapy: Benzathine pe Other (therap ted by panel p e of syphilis (i	enicillin, <i>y, dose)</i> ohysicia	n:	IM Yes	-dd-yy	<i>yy)</i>			Initial Titer		
Co Tr	onfirma eated Yes	tory If tre	ated, therapy: Benzathine pe Other (<i>therap</i> ted by panel p e of syphilis (Primary	enicillin, <i>y, dose)</i> ohysicia	n:	IM U Yes	e-dd-yy	<i>yy)</i>			Initial Titer		
Co Tr	onfirma eated Yes	tory If tre	ated, therapy: Benzathine pe Other (therapy ted by panel p e of syphilis (Primary Secondary	enicillin, y, dose) ohysicia mark on	n:	IM Tertiar Neuros	y y y y y y y y y y y y hilis	<i>yy)</i>			Initial Titer		
Co Tr	onfirma eated Yes	tory If tre	ated, therapy: Benzathine pe Other (therapy ted by panel p e of syphilis (Primary Secondary Early latent	: enicillin, y, dose) ohysicia mark on	: n: ne):	IM U Yes	y y y y y y y y y y y y hilis	<i>yy)</i>			Initial Titer		
Co Tr	onfirma eated Yes	tory If tre	ated, therapy: Benzathine pe Other (therapj ted by panel j e of syphilis (Primary Secondary Early latent Late latent of	enicillin, y, dose) bhysicia mark on	: n: ne):	IM Tertiar Neuros	y y y y y y y y y y y y hilis	<i>yy)</i>			Initial Titer		
Co Tr	onfirma eated Yes	tory If tre	ated, therapy: Benzathine pe Other (therapy ted by panel p e of syphilis (Primary Secondary Early latent	enicillin, y, dose) bhysicia mark on	: n: ne):	IM Tertiar Neuros	y y y y y y y y y y y y hilis	<i>yy)</i>			Initial Titer		
	onfirma eated Yes No	tory If tre	ated, therapy: Benzathine pe Other (therapj ted by panel j e of syphilis (Primary Secondary Early latent Late latent of	enicillin, y, dose) ohysicia mark on por latent uration	n: ne):	IM Tertiar Neuros Conge	y syphilis nital	уу)] No	Date(s) treatment g		Initial Titer		
8. D	eated Yes No	tory If tre	ated, therapy: Benzathine pe Other (therapy ted by panel p e of syphilis (Primary Secondary Early latent Late latent o unknown du	enicillin, y, dose) ohysicia mark on or latent uration f Other	n:ne): ne): of Sexuall	IM IM Tertiar Neuros Conge y Transmitte	y syphilis nital	No	Date(s) treatment g	iven (mm-dd-yyyy)	Initial Titer		
Ct Tr Ct State 8. D Infe	onfirma eated Yes No No	tory If tre Trea Stag Stag Stag Stag Char is and	ated, therapy: Benzathine pe Other (therap) ted by panel p e of syphilis (Primary Secondary Early latent Late latent of unknown du Treatment of ancroid	enicillin, y, dose) ohysicia mark on or latent <u>iration</u> f Other Gonorrhe	n: ne): of Sexuall	IM IM Tertiar Neuros Conge y Transmitte Granuloma ir	y syphilis nital	No	Date(s) treatment g	iven (mm-dd-yyyy)			
Ct Tr Ct State 8. D Infe	eated eated Yes No iagnos	tory If tre Trea Stag Stag Stag Stag Char is and	ated, therapy: Benzathine pe Other (therapy ted by panel p e of syphilis (Primary Secondary Early latent Late latent of Treatment of	enicillin, y, dose) ohysicia mark on or latent uration f Other	n: ne): of Sexuall	IM IM Tertiar Neuros Conge y Transmitte	y syphilis nital	No	Date(s) treatment g	iven (mm-dd-yyyy)	Initial Titer		
Ct Tr Ct State 8. D Infe	eated eated Yes No iagnos	tory If tre Trea Stag Stag Stag Stag Char is and	ated, therapy: Benzathine pe Other (therap) ted by panel p e of syphilis (Primary Secondary Early latent Late latent of unknown du Treatment of ancroid	enicillin, y, dose) ohysicia mark on or latent <u>iration</u> f Other Gonorrhe	n: ne): of Sexuall	IM IM Tertiar Neuros Conge y Transmitte Granuloma ir	y syphilis nital	No	Date(s) treatment g	iven (mm-dd-yyyy)			
Ct Tr Ct State 8. D Infe	eated eated Yes No iagnos	tory If tre Trea Stag Stag Stag Stag Char is and	ated, therapy: Benzathine pe Other (therap) ted by panel p e of syphilis (Primary Secondary Early latent Late latent of unknown du Treatment of ancroid	enicillin, y, dose) ohysicia mark on or latent <u>iration</u> f Other Gonorrhe	n: ne): of Sexuall	IM IM Tertiar Neuros Conge y Transmitte Granuloma ir	y syphilis nital	No	Date(s) treatment g	iven (mm-dd-yyyy)			
Ct Tr Ct State 8. D Infe	eated eated Yes No iagnos	tory If tre Trea Stag Stag Stag Stag Char is and	ated, therapy: Benzathine pe Other (therap) ted by panel p e of syphilis (Primary Secondary Early latent Late latent of unknown du Treatment of ancroid	enicillin, y, dose) ohysicia mark on or latent <u>iration</u> f Other Gonorrhe	n: ne): of Sexuall	IM IM Tertiar Neuros Conge y Transmitte Granuloma ir	y syphilis nital	No	Date(s) treatment g	iven (mm-dd-yyyy)			
Ct Tr Ct State 8. D Infe	eated eated Yes No iagnos	tory If tre Trea Stag Stag Stag Stag Char is and	ated, therapy: Benzathine pe Other (therap) ted by panel p e of syphilis (Primary Secondary Early latent Late latent of unknown du Treatment of ancroid	enicillin, y, dose) ohysicia mark on or latent <u>iration</u> f Other Gonorrhe	n: ne): of Sexuall	IM IM Tertiar Neuros Conge y Transmitte Granuloma ir	y syphilis nital	No	Date(s) treatment g	iven (mm-dd-yyyy)			
Ct Tr Ct State 8. D Infe	eated eated Yes No iagnos	tory If tre Trea Stag Stag Stag Stag Char is and	ated, therapy: Benzathine pe Other (therap) ted by panel p e of syphilis (Primary Secondary Early latent Late latent of unknown du Treatment of ancroid	enicillin, y, dose) ohysicia mark on or latent <u>iration</u> f Other Gonorrhe	n: ne): of Sexuall	IM IM Tertiar Neuros Conge y Transmitte Granuloma ir	y syphilis nital	No	Date(s) treatment g	iven (mm-dd-yyyy)			

9. Diagnosis and Treatment for Hansen's Disease											
Type of Hansen's Disease Treatment	Drug	Dosage	Start Date (mm-dd-yyyy)	End Date (mm-dd-yyyy)							
Multibacillary Partial	Diag	Doougo									
Paucibacillary Completed											
Treated by panel physician											
□ Yes											
□ No											
If not treated by panel physician, was referral made	e by panel physician to an	other provider fo	r treatment:								
Yes. Provide facility name:											
□ No											
Diagnosis											
□ Initial diagnosis made by panel physician											
 Initial diagnosis made by non-panel physician) before medical evaluation	n by panel physi	cian								
If so, year of diagnosis:											
10. Remarks											
PAPERWORK REDUCTION ACT STATEME	 ENT										
Public reporting burden for this collection of in	formation is estimated to a	average 30 minu	tes per response, including time	e required for							
searching existing data sources, gathering the											
reviewing the final collection. You do not have number. If you have comments on the accura											
PRA_BurdenComments@state.gov	ley of this burden estimate		endations for reducing it, please	send them to.							
CONFIDENTIALITY STATEMENT											
				ing al law Operations 2000 of the							
AUTHORITIES The information asked for on Immigration and Nationality Act. Section 222			., ., .	-							
the United States pertaining to the issuance a											
be used only for the formulation, amendment,	•										
Certified copies of such records may, in the discretion of the Secretary of State, be made available to a court provided the court certifies that the											
information contained in such records is needed in a case pending before the court.											
PURPOSE The U.S. Department of State up	DUDDOSE. The U.S. Department of State uses the facts you provide on this form primarily to determine your electification and eligibility for a										
PURPOSE The U.S. Department of State uses the facts you provide on this form primarily to determine your classification and eligibility for a U.S. immigrant visa. Individuals who fail to submit this form or who do not provide all the requested information may be denied a U.S. immigrant											
visa. Although furnishing this information is voluntary, failure to provide this information may delay or prevent the processing of your case.											
ROUTINE USES If you are issued an immigr											
Homeland Security will use the information on this form to issue you a Permanent Resident Card, and, if you so indicate, the Social Security Administration will use the information to issue a social security number. The information provided may also be released to federal agencies for											
	law enforcement, counterterrorism and homeland security purposes; to Congress and courts within their sphere of jurisdiction; and to other										
federal agencies who may need the information to administer or enforce U.S. laws. More information on the Routine Uses for this collection can											
be found in the System of Records Notice Sta											